FROM 21 FEBRUARY 2020 – TO 30 NOVEMBER 2020 (17:00 CET)
India has launched a Globalstars call for projects with Austria, Belgium (Flanders), Finland, France, the Netherlands, Sweden and Switzerland with the scope: “key enabling technologies for healthcare, agriculture and water”. Participants from India and respective Eureka countries are invited to submit joint industrial R&D project proposals within the framework of the Eureka network.
Bilateral consortia (one Indian partner with one partner from countries listed above) are eligible, but multilateral consortia (Indian partner with partners from multiple countries listed above) are warmly welcomed as well.
Scope
This call invites consortia to apply high quality R&D projects within the scope “key enabling technologies for healthcare, agriculture and water”. These should be collaborative research and innovation projects that apply key enabling technologies (chemical technologies, digital technologies, engineering technologies, advanced materials, biotechnologies, micro- & nanotechnologies) to tackle challenges in healthcare, agriculture or water, resulting in innovative, affordable, accessible and marketable solutions. Projects aiming to provide responses to (post) COVID-19-specific needs are warmly welcome as well.
For example:
- Biotechnologies and digital technologies for infection prevention, tracking and monitoring;
- Engineering technologies for affordable medical devices, accessible and easily usable for (community) health professionals;
- Nanotechnology in filtration for water purification, deliver safe drinking water;
- Digital technologies for evidence based, interoperable digital health services, deliver affordable (tele-)healthcare in rural areas;
- Biotechnologies in sustainable agriculture production and productivity, increase crop yields and disease resistant varieties;
- Digital and engineering technologies for smart farming and precision agriculture;
- Chemical- and biotechnologies for reducing non-communicable diseases, towards safer, personalised and more affordable therapeutics to improve quality of life.
